Search Results for: viacyte

Clade Therapeutics pursues universal cells for cancer therapy

Chad-Cowan CRISPR Therapeutics

Clade  Therapeutics has been pursuing the idea of using gene-editing to make universally compatible cells. The potential here is big. What if you could make cloaked stem cells that could be used to produce cellular therapies that could be given to most patients without fear of immune rejection? Clade Therapeutics Boston Business Journal covers the […]

Clade Therapeutics pursues universal cells for cancer therapy Read More »

Vertex upbeat on 1st stem cell therapy for diabetes trial participant

“While still early, these results support the continued progression of our VX-880 clinical studies, as well as future studies using our encapsulated islet cells, which hold the potential to be used without the need for immunosuppression,” said Bastiano Sanna, Ph.D., executive vice president and chief of cell and genetic therapies at Vertex.

It’s hard in the cell therapy field not to get excited even with bits of seemingly encouraging news but with N=1 reports we have to be very cautious and that’s the case with news from Vertex on their 1st stem cell therapy for diabetes trial participant. Vertex stem cell therapy for diabetes VX-880: N=1 This

Vertex upbeat on 1st stem cell therapy for diabetes trial participant Read More »

Stem cell therapy for diabetes updates: expected IPO, CRISPR, new pubs, more

stem cell therapy for diabetes

The idea of stem cell therapy for diabetes is both exciting and in a way practical. By that I mean that there’s a good common sense foundation here. The idea of stem cell therapy for diabetes What do I mean? If medical researchers can replace lost beta cells in the pancreas using stem cell-produced beta

Stem cell therapy for diabetes updates: expected IPO, CRISPR, new pubs, more Read More »

24 cell therapy & stem cell stocks I’m following

stem cell stocks

Stem cell stocks, meaning cellular therapy biotech companies, face many challenges, but their clinical research is crucial. Stem cell biotechs These biotechs have ups and downs, sometimes at the same time. This is kind of the standard of “life” as any biotech company. It is definitely the case in the volatile stem cell and cell

24 cell therapy & stem cell stocks I’m following Read More »

20/20 vision? The Niche’s 20 stem cell & regenerative medicine predictions for 2020

The-Niche-stem-cell-predictions-2020

Every year in December and early January I do a post predicting some key events for the stem cell and regenerative medicine field for the upcoming year and today’s post contains my predictions for 2020. You can see my past 2019 predictions along with my grades for them here. I gave myself a B+ for

20/20 vision? The Niche’s 20 stem cell & regenerative medicine predictions for 2020 Read More »

B+ on my report card on my 20 stem cell predictions for 2019

stem-cell-crystal-ball-predictions-1

Last year around this time I took my annual plunge to make 20 predictions for the coming year for the stem cell and regenerative medicine field. I even made a crystal ball graphic to highlight the complexity of the stem cell ecosystem into which these predictions were embedded (see image) for 2019. How’d I do?

B+ on my report card on my 20 stem cell predictions for 2019 Read More »